29 / 32
Rationale for using 1
st
-2
nd
generation EGFR TKI first
•
Good treatment outcomes with sequential
1
st
-2
nd
generation
followed
by osimertinib in T790M+
•
Resistance mechanism after PD with 1L osimertinib
•
Appropriate therapy after 1L osimertinib PD, not well defined